Share on WeChat
https://www.powervoter.us:443/tom_cotton
Copy the link and open WeChat to share.
 Share on WeChat
Copy the link and open WeChat to share.
 Share on WeChat
Scan QRCode using WeChat,and then click the icon at the top-right corner of your screen.
 Share on WeChat
Scan QRCode using WeChat,and then click the icon at the top-right corner of your screen.

Tom Cotton

R
Quick Facts
Personal Details

Education

  • JD, Harvard Law School, 1999-2002
  • AB, Government, Harvard University, 1995-1999
  • Attended, Claremont Graduate University, California, 1998-1999

Professional Experience

  • JD, Harvard Law School, 1999-2002
  • AB, Government, Harvard University, 1995-1999
  • Attended, Claremont Graduate University, California, 1998-1999
  • Served, United States Army Reserve, 2010-2013
  • Management Consultant, McKinsey & Company, 2010-2011
  • Captain, United States Army, 2005-2009
  • Attorney, Cooper & Kirk, 2004
  • Attorney, Gibson Dunn & Crutcher, 2003-2004
  • Judicial Clerk, United States Court of Appeals, 2002-2003

Political Experience

  • JD, Harvard Law School, 1999-2002
  • AB, Government, Harvard University, 1995-1999
  • Attended, Claremont Graduate University, California, 1998-1999
  • Served, United States Army Reserve, 2010-2013
  • Management Consultant, McKinsey & Company, 2010-2011
  • Captain, United States Army, 2005-2009
  • Attorney, Cooper & Kirk, 2004
  • Attorney, Gibson Dunn & Crutcher, 2003-2004
  • Judicial Clerk, United States Court of Appeals, 2002-2003
  • Senator, United States Senate, Arkansas, 2014-present
  • Candidate, United States Senate, Arkansas, 2014, 2020
  • Representative, United States House of Representatives, Arkansas, District 4, 2012-2014
  • Candidate, United States House of Representatives, Arkansas, District 4, 2012

Former Committees/Caucuses

Former Member, Budget Committee, United States Senate

Former Member, Financial Institutions and Consumer Protection Subcommittee, United States Senate

Former Member, National Security and International Trade and Finance Subcommittee, United States Senate

Former Member, Special Committee on Aging, United States Senate

Former Member, Subcommittee on Emerging Threats and Capabilities, United States Senate

Former Member, Subcommittee on Housing, Transportation, and Community Development, United States Senate

Former Member, Subcommittee on Personnel, United States Senate

Current Legislative Committees

Member, Armed Services

Member, Banking, Housing, and Urban Affairs

Member, Joint Economic Committee

Member, Select Committee on Intelligence

Chair, Subcommittee on Airland

Chair, Subcommittee on Economic Policy

Member, Subcommittee on Housing, Transportation, and Community Development

Member, Subcommittee on Seapower

Member, Subcommittee on Securities, Insurance, and Investment

Member, Subcommittee on Strategic Forces

Religious, Civic, and other Memberships

  • JD, Harvard Law School, 1999-2002
  • AB, Government, Harvard University, 1995-1999
  • Attended, Claremont Graduate University, California, 1998-1999
  • Served, United States Army Reserve, 2010-2013
  • Management Consultant, McKinsey & Company, 2010-2011
  • Captain, United States Army, 2005-2009
  • Attorney, Cooper & Kirk, 2004
  • Attorney, Gibson Dunn & Crutcher, 2003-2004
  • Judicial Clerk, United States Court of Appeals, 2002-2003
  • Senator, United States Senate, Arkansas, 2014-present
  • Candidate, United States Senate, Arkansas, 2014, 2020
  • Representative, United States House of Representatives, Arkansas, District 4, 2012-2014
  • Candidate, United States House of Representatives, Arkansas, District 4, 2012
  • Member, Editorial Board, Harvard Crimson
  • Member, United Methodist Church

Other Info

— Awards:

  • Bronze Star Medal, Ranger Tab, Combat Infantryman Badge, Parachutist Badge, Air Assault Badge, Afghanistan Campaign Medal, Iraq Campaign Medal, Army Commendation Medal (with oak leaf cluster), Army Achievement Medal, Air Force Achievement Medal, NATO Service Medal

  • Len Cotton

  • Former District Supervisor, Arkansas Department of Health

Favorite Author:

Walter Russell Mead, Robert D. Kaplan, Henry Kissinger, Daniel Silva, C.J. Vonn, and Jason Matthews

  • Avis Cotton

  • Former Middle School Principal

Policy Positions

2020

Abortion

1. Do you generally support pro-choice or pro-life legislation?
- Pro-life

Budget

1. In order to balance the budget, do you support an income tax increase on any tax bracket?
- No

2. Do you support expanding federal funding to support entitlement programs such as Social Security and Medicare?
- Unknown Position

Campaign Finance

Do you support the regulation of indirect campaign contributions from corporations and unions?
- Unknown Position

Crime

Do you support the protection of government officials, including law enforcement officers, from personal liability in civil lawsuits concerning alleged misconduct?
- Unknown Position

Defense

Do you support increasing defense spending?
- Yes

Economy

1. Do you support federal spending as a means of promoting economic growth?
- Yes

2. Do you support lowering corporate taxes as a means of promoting economic growth?
- Yes

3. Do you support providing financial relief to businesses AND/OR corporations negatively impacted by the state of national emergency for COVID-19?
- Yes

Education

1. Do you support requiring states to adopt federal education standards?
- No

Energy and Environment

1. Do you support government funding for the development of renewable energy (e.g. solar, wind, geo-thermal)?
- Unknown Position

2. Do you support the federal regulation of greenhouse gas emissions?
- No

Guns

1. Do you generally support gun-control legislation?
- No

Health Care

1. Do you support repealing the 2010 Affordable Care Act ("Obamacare")?
- Yes

2. Do you support requiring businesses to provide paid medical leave during public health crises, such as COVID-19?
- Yes

Immigration

1. Do you support the construction of a wall along the Mexican border?
- Yes

2. Do you support requiring immigrants who are unlawfully present to return to their country of origin before they are eligible for citizenship?
- Yes

National Security

1. Should the United States use military force to prevent governments hostile to the U.S. from possessing a weapon of mass destruction (for example: nuclear, biological, chemical)?
- Unknown Position

2. Do you support reducing military intervention in Middle East conflicts?
- Unknown Position

Trade

Do you generally support removing barriers to international trade (for example: tariffs, quotas, etc.)?
- Unknown Position

2019

Abortion

1. Do you generally support pro-choice or pro-life legislation?
- Pro-life

Budget

1. In order to balance the budget, do you support an income tax increase on any tax bracket?
- No

Economy

1. Do you support federal spending as a means of promoting economic growth?
- No

Education

1. Do you support requiring states to implement education reforms in order to be eligible for competitive federal grants?
- No

Energy

Do you support building the Keystone XL pipeline?
- Yes

Environment

Do you support the federal regulation of greenhouse gas emissions?
- Unknown Position

Guns

1. Do you support restrictions on the purchase and possession of guns?
- No

Health Care

1. Do you support repealing the 2010 Affordable Care Act?
- Yes

Immigration

1. Do you support requiring illegal immigrants to return to their country of origin before they are eligible for citizenship?
- Yes

Marriage

Do you support same-sex marriage?
- No

National Security

1. Do you support targeting suspected terrorists outside of official theaters of conflict?
- Unknown Position

Social Security

Do you support allowing individuals to divert a portion of their Social Security taxes into personal retirement accounts?
- Unknown Position

Congress Bills
Speeches
Articles

The Wall Street Journal - Cotton: Coronavirus and the Laboratories in Wuhan

Apr. 21, 2020

By Tom Cotton The U.S. government is investigating whether the Covid-19 virus came from a government laboratory in Wuhan, China. The Chinese Communist Party denies the possibility. "There is no way this virus came from us," claimed Yuan Zhiming over the weekend. Mr. Yuan is a top researcher at the Wuhan Institute of Virology, which studies some of the world's deadliest pathogens. He is also secretary of the lab's Communist Party committee. He accuses me of "deliberately trying to mislead people" for suggesting his laboratory as a possible origin for the pandemic. Beijing has claimed that the virus originated in a Wuhan "wet market," where wild animals were sold. But evidence to counter this theory emerged in January. Chinese researchers reported in the Lancet Jan. 24 that the first known cases had no contact with the market, and Chinese state media acknowledged the finding. There's no evidence the market sold bats or pangolins, the animals from which the virus is thought to have jumped to humans. And the bat species that carries it isn't found within 100 miles of Wuhan. Wuhan has two labs where we know bats and humans interacted. One is the Institute of Virology, eight miles from the wet market; the other is the Wuhan Center for Disease Control and Prevention, barely 300 yards from the market. Both labs collect live animals to study viruses. Their researchers travel to caves across China to capture bats for this purpose. Chinese state media released a minidocumentary in mid-December following a team of Wuhan CDC researchers collecting viruses from bats in caves. The researchers fretted openly about the risk of infection. These risks were not limited to the field. The Washington Post reported last week that in 2018 U.S. diplomats in China warned of "a serious shortage of appropriately trained technicians and investigators needed to safely operate" the Institute of Virology. The Wuhan CDC operates at even lower biosafety standards. While the Chinese government denies the possibility of a lab leak, its actions tell a different story. The Chinese military posted its top epidemiologist to the Institute of Virology in January. In February Chairman Xi Jinping urged swift implementation of new biosafety rules to govern pathogens in laboratory settings. Academic papers about the virus's origins are now subject to prior restraint by the government. In early January, enforcers threatened doctors who warned their colleagues about the virus. Among them was Li Wenliang, who died of Covid-19 in February. Laboratories working to sequence the virus's genetic code were ordered to destroy their samples. The laboratory that first published the virus's genome was shut down, Hong Kong's South China Morning Post reported in February. This evidence is circumstantial, to be sure, but it all points toward the Wuhan labs. Thanks to the Chinese coverup, we may never have direct, conclusive evidence-intelligence rarely works that way-but Americans justifiably can use common sense to follow the inherent logic of events to their likely conclusion.

Fox News - Op Ed by Sen. Tom Cotton and Rep. Mike Gallagher: Sen. Cotton and Rep. Gallagher: China stole US capacity to make drugs -- we must take it back

Mar. 25, 2020

By Sen. Tom Cotton and Rep. Mike Gallagher Earlier this month, a Chinese Communist Party propaganda outlet insinuated that Beijing could cut off supplies of life-saving medicine to the United States at any time, dooming our country to "sink into the hell of a novel coronavirus epidemic." Unfortunately, this isn't an empty threat. The United States is dangerously dependent for pharmaceuticals on the very regime whose failures and coverups caused this deadly pandemic to spiral out of control. It's time to change that. We have a plan to end America's dependence on Chinese drugs and take back our ability to make pharmaceuticals and medical devices right here in America. We weren't always dependent on China for medicine, but we are now. For two decades, the CCP has targeted America's domestic drug manufacturers for destruction, using cartelization, state subsidies and lax safety standards to flood our hospitals and pharmacies with cheap and dangerous Chinese medicine. This strategy succeeded in shuttering American factories, robbing our workers of good-paying jobs and our patients of high-quality medicine. Just years after the United States granted China special trade privileges in 2000, the last penicillin plant in America closed down. American factories that made aspirin, vitamin C and other essential medicine closed after that, put out of business by China's predatory pricing. China has come to dominate the world market for basic drugs as a result. A substantial share of all generic drugs we import comes from China, including a staggering 93 percent of all imported ibuprofen. And focusing on direct trade between China and the United States actually understates our reliance, because most of the active ingredients in drugs imported to us from countries like India also come from Chinese superlabs. Dependence on our chief communist adversary for essential medicine is an obvious threat to national security. As Rosemary Gibson, author of "China Rx: Exposing the Risks of America's Dependence on China for Medicine," said in testimony before the U.S.-China Economic and Security Review Commission last year, if the CCP cut the world off from its pharmaceutical ingredients, "military hospitals and clinics would cease to function within months, if not days." This may seem like an extreme and remote possibility, but consider that multiple countries have already hoarded drugs and medical supplies in response to the China virus pandemic. China itself is hoarding much of the world's supply not only of medical masks, but also of the materials to make those masks. Emergencies like pandemics and wars break down previously dependable supply chains and relationships as nations start to fend for themselves. It's sadly clear America gave up the ability to fend for ourselves in basic medicine long ago. But dependence on China for basic drugs threatens our safety in a more basic way. The drugs China produces are notoriously low quality, even deadly. This fact became tragically apparent in 2008, when more than 246 Americans were killed by a tainted batch of blood thinner that was made in China. Investigations later revealed that the blood thinner had been spiked with cheaper drugs to save money at unregulated labs and farms in China. Even the CCP itself has acknowledged the poor quality of its drugs. Beijing suspended a program to bribe African countries with anti-malarial drugs in 2012 after entire shipments were found to be fake, posing a danger to the sick patients who took them. As the China virus pandemic clearly shows, the CCP has no business posing as the world's doctor and drugmaker. That's why we've introduced a bill, the Protecting Our Pharmaceutical Supply Chain From China Act, to end our dependence on Chinese drugs and take back our ability to make medicine here at home. Our bill would require federal entities like the Department of Defense, VA hospitals, Medicare and Medicaid to cut off purchases of drugs with Chinese ingredients no later than 2025. This requirement would phase in over a period of years to give drug companies time to adjust, but would put clear pressure on importers to stop doing business with the CCP. The bill also would require drug companies to label the origins of ingredients in their drugs, so U.S. consumers are better informed of where their medicine comes from and whether it's likely to be safe. Finally, our bill encourages the medical industry to manufacture in our country again by offering full and immediate expensing of factories, warehouses and capital goods related to the manufacture of drugs and medical devices on American soil. This bill poses a threat to China's ambitions, and the CCP knows it. Earlier this week, a Communist Party spokesman responded to the growing clamor in America for medical repatriation by saying that China's dominance in pharmaceutical manufacturing was the inevitable result of "market forces" that would be "unrealistic and insensible" to sever. Set aside the irony of a Communist Party spokesman for a mercantilist regime lauding the power of market forces; there's nothing inevitable about our dependence on China for medicine. That dependence was the result of the CCP's ruthless tactics, abetted by bad decisions by American policymakers and business people over many years. We can begin to undo the damage now. The antidote to our dependence on Chinese drugs is to stop buying them and take back our ability to make basic medicine here in America.